Atea Pharmaceuticals(AVIR.US) Director Sells US$61,144.35 in Common Stock

$Atea Pharmaceuticals(AVIR.US)$ Director Polsky Bruce sold 17,544 shares of common stock on Jun 20, 2024 at an average price of $3.4852 for a total value of $61,144.35.Source: Announcement What is sta

Moomoo NewsJun 21 18:40 ET

Atea Pharmaceuticals(AVIR.US) Officer Sells US$4,024 in Common Stock

$Atea Pharmaceuticals(AVIR.US)$ Officer Sommadossi Jean-Pierre sold 1,006 shares of common stock on Jun 5, 2024 at an average price of $4 for a total value of $4,024.Source: Announcement What is state

moomoo NewsJun 7 19:15 ET

Morgan Stanley Initiates Atea Pharmaceuticals(AVIR.US) With Sell Rating, Announces Target Price $2

Morgan Stanley analyst Maxwell Skor initiates coverage on $Atea Pharmaceuticals(AVIR.US)$ with a sell rating, and sets the target price at $2.According to TipRanks data, the analyst has a success rate

moomoo NewsJun 5 17:32 ET

Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus

Atea Pharmaceuticals Inc (NASDAQ:AVIR) announced Wednesday new data from the lead-in cohort (n=60) of the company's ongoing Phase 2 combination study of bemnifosbuvir for hepatitis C virus (HCV).With

BenzingaJun 5 10:55 ET

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High

GlobeNewswireJun 5 07:00 ET

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious

GlobeNewswireMay 29 07:00 ET